期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

动脉序贯化疗预防浸润性膀胱癌术后复发23例 被引量：1

原文传递
导出
摘要 目的探讨经化疗泵序贯注射抗癌药对浸润性膀胱癌术后的治疗效果。方法对23例浸润性膀胱癌患者行膀胱部分切除术。术中经髂内动脉置入化疗泵。术后经化疗泵序贯注射吡柔比星（THP）20mg，顺铂40mg，氟尿嘧啶500mg，每次一种药。从术后第1周开始，每周1次。6次后改为每2周1次，然后每月1次至术后2年。结果23例随访6个月-3年，平均22个月。无复发者19例，有效率82．6％，术后3、7、11个月各复发1例，1例于术后16个月出现腹腔肝转移。结论髂内动脉置化疗泵序贯注射抗癌药可作为预防浸润性膀胱癌术后复发的辅助治疗。
作者 石红林 李启忠
机构地区 河南省人民医院泌尿外科
出处 《肿瘤研究与临床》 CAS 2007年第2期120-121,共2页 Cancer Research and Clinic
关键词 膀胱肿瘤 肿瘤浸润 抗肿瘤联合化疗方案
分类号 R737 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1Caffo O, Fellin G, Grafter U, et al. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma.A survey by a self-administered questionnaire [J]. Cancer, 1996, 78(5): 1089-1097.
  • 2Skinner D G, Daniels J R, Russell C A, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial[J]. J Urol, 1991, 145(3): 459-464.
  • 3Raghavan D, Shipley W U, Garnick M B, et al. Biology and management of bladder cancer[J]. N Engl J Mod, 1990, 322(16): 1129-1138.
  • 4Herr H W, Scher H I. Neoadjavant chemotherapy and partial Cystectomy for invasive bladder eaneer[J].J Clin Oncol, 1994, 12(5): 975-980.
  • 5Srougi M, Simon Z D. Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5-year follow up[J]. J Urol, 1994, 151(3): 593-597.
  • 6Tochigi H, Hayashi N, Hoskin A, et al. Tissue platinum concentration following preoperative balder occluded arterial infusion (BOAI) for bladder cancer[J]. J Jpn Soc Cancer Ther, 1995, 30(2): 841- 847.
  • 7Setsuko K. Rapid uptake by cultured tumor cells and intracellular behavior of 4-o-tetrahydmpyranyladriamycin[J]. J Antibiot, 1983,36(4): 312-315,

同被引文献20

  • 1李劲松,徐兴钊,丁吉元,曾林.膀胱移行细胞癌患者预后因素的多元分析[J].中华外科杂志,1995,33(6):353-354. 被引量：4
  • 2LAMM DL. Prophylaxis for recmxent transitional cell carcinoma [J]. Urology, 1991, 37(Suppl 5): 21-23.
  • 3FORD JM, HAIT WN. Pharmacology of drugs that alter mul- tidrug resistance in cancer[J]. Pharmocol Rev, 1990, 42(3): 155- 199.
  • 4BELLIVEAU JF, POSNER MR, FERRARIL, et al. Cisplatinad- nainisteredasacontinuouss-dayinfusion: plasmaplat inuousleveisan- durineexeretion[J]. Cancev Tveat Rep, 1986, 70: 1215-1217.
  • 5LEHANE DE. Intra-arterial cisplatinum in advanced solid tu- mors. In: Howell SB, ed. Intra-arterial and intracavitary cancer chemotherapy[M]. Boston: Martinus Nijhoff, 1984: 1-10.
  • 6JACOBS SC, MMEASHE DS, MEWISSEN MW, et al. Intraar- terial cisplatin infu 2 sion in the management of transitional cell carcinoma of the bladder[J]. Can 2 cer, 1989, 64: 388-391.
  • 7TSUKARNOTO S, ISHIKAWA S, TSUTSUNI M, et al. An or- gan-sparing treatment using intra-arterial chemotherapy and ra- diotherapy for muscle-invading bladder carcinoma[J]. Scand J Urol Nephrol, 2002, 36: 339-343.
  • 8ZHOU FJ, YU SL, LI YH. et al. Intra-arterial chemotherapy with geeitabine and eisplatin for patients with recurrence of transitional cell carcinoma confined to the pelvis[J]. J Chemother apy, 2009, 21: 91-97.
  • 9VON DER MAASE H, HANSEN SW, ROBERTS JT, et al. Gemeitabine and eisplatin versus methotrexate, vinblastine, dox- orubiein, and eisplatin in advanced or metastatie bladder can- eer: results of a large, randomized, muhinational, muhicenter, phase Ⅲ study[J]. J Clin Oncol, 2000, 18: 3068-3077.
  • 10NAKAGAWA S, KOJIMA M, TAKADA H, et al. Short-duration bladder instillation therapy with pirarubicin for superficial blad- der tumor based on pharmacodynamic study[J]. Gan To Kagaku Ryoho, 1992, 19(11): 1873-1877.

引证文献1

二级引证文献3

肿瘤研究与临床
2007年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部